PriceTargets.com logo

Instil Bio - TIL Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $110.00
  • Forecasted Upside: 161.47%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$42.07 As of 10/11/2024 01:00 AM ET
▲ +4.58 (12.22%)

This chart shows the closing price for TIL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Instil Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TIL

Analyst Price Target is $110.00
▲ +161.47% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Instil Bio in the last 3 months. The average price target is $110.00, with a high forecast of $180.00 and a low forecast of $40.00. The average price target represents a 161.47% upside from the last price of $42.07.

This chart shows the closing price for TIL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 contributing investment analysts is to moderate buy stock in Instil Bio. This rating has held steady since October 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/13/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/11/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/13/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$32.00 ➝ $180.00
9/12/2024HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $40.00
8/23/2024HC WainwrightBoost TargetBuy ➝ Buy$18.00 ➝ $25.00
8/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00
5/13/2024Robert W. BairdLower TargetOutperform ➝ Outperform$54.00 ➝ $32.00
4/12/2024Jefferies Financial GroupDowngradeBuy ➝ Hold
3/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00
1/22/2024HC WainwrightBoost TargetBuy ➝ Buy$18.00
1/17/2024Robert W. BairdLower TargetOutperform ➝ Outperform$100.00 ➝ $54.00
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$40.00
8/17/2023HC WainwrightReiterated RatingBuy ➝ Buy$40.00
6/29/2023HC WainwrightReiterated RatingBuy
4/5/2023Truist FinancialReiterated RatingHold$120.00
12/12/2022Morgan StanleyLower TargetEqual Weight$120.00 ➝ $40.00
12/9/2022Robert W. BairdLower Target$280.00 ➝ $100.00
11/17/2022Robert W. BairdLower TargetOutperform$480.00 ➝ $280.00
11/1/2022Morgan StanleyLower TargetEqual Weight$160.00 ➝ $120.00
11/1/2022Truist FinancialDowngradeBuy ➝ Hold$320.00 ➝ $120.00
11/1/2022Robert W. BairdLower TargetOutperform$620.00 ➝ $480.00
11/1/2022CowenDowngradeOutperform ➝ Market Perform
11/1/2022CowenDowngradeOutperform ➝ Market Perform
9/6/2022Robert W. BairdLower TargetOutperform$680.00 ➝ $620.00
8/24/2022Morgan StanleyLower TargetEqual Weight$180.00 ➝ $160.00
8/23/2022Truist FinancialLower TargetBuy$500.00 ➝ $320.00
6/5/2022Morgan StanleyLower TargetEqual Weight$280.00 ➝ $180.00
5/27/2022Truist FinancialLower Target$500.00
5/24/2022Morgan StanleyLower TargetEqual Weight$300.00 ➝ $280.00
8/12/2021Robert W. BairdInitiated CoverageOutperform$680.00
5/26/2021Morgan StanleyLower TargetEqual Weight$480.00 ➝ $460.00
4/19/2021Truist FinancialInitiated CoverageBuy$640.00
4/19/2021CowenInitiated CoverageOutperform
4/19/2021Morgan StanleyInitiated CoverageEqual Weight$480.00
4/19/2021Jefferies Financial GroupInitiated CoverageBuy$620.00
4/13/2021Truist FinancialInitiated CoverageBuy$640.00
4/13/2021Jefferies Financial GroupInitiated CoverageBuy$620.00
4/13/2021Morgan StanleyInitiated CoverageEqual Weight$480.00
4/13/2021CowenInitiated CoverageOutperform
(Data available from 10/12/2019 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/15/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/15/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/14/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/13/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/12/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/12/2024

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Instil Bio logo
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Read More

Today's Range

Now: $42.07
Low: $35.68
High: $42.07

50 Day Range

MA: $33.03
Low: $10.06
High: $84.52

52 Week Range

Now: $42.07
Low: $6.07
High: $92.00

Volume

189,172 shs

Average Volume

95,268 shs

Market Capitalization

$273.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Instil Bio?

The following sell-side analysts have issued reports on Instil Bio in the last year: HC Wainwright, Jefferies Financial Group Inc., Robert W. Baird, and StockNews.com.
View the latest analyst ratings for TIL.

What is the current price target for Instil Bio?

2 Wall Street analysts have set twelve-month price targets for Instil Bio in the last year. Their average twelve-month price target is $110.00, suggesting a possible upside of 161.5%. Robert W. Baird has the highest price target set, predicting TIL will reach $180.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $40.00 for Instil Bio in the next year.
View the latest price targets for TIL.

What is the current consensus analyst rating for Instil Bio?

Instil Bio currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TIL.

What other companies compete with Instil Bio?

Other companies that are similar to Instil Bio include Gyre Therapeutics, Cassava Sciences, Collegium Pharmaceutical, Avadel Pharmaceuticals and Day One Biopharmaceuticals. Learn More about companies similar to Instil Bio.

How do I contact Instil Bio's investor relations team?

Instil Bio's physical mailing address is CONTINENTAL BUILDING 25 CHURCH STREET, HAMILTON D0, HM1Z. The company's listed phone number is 972-499-3350 and its investor relations email address is [email protected]. The official website for Instil Bio is www.tillcap.com. Learn More about contacing Instil Bio investor relations.